Sponsored by
Medulloblastoma has four major molecular subgroups. In high-risk groups 3 and 4, the tumors can have changes in the way DNA is packaged and controlled. Recent preclinical research from St Jude and collaborators has identified a potential vulnerability involving a protein called KDM2B, which appears to help these tumor cells maintain their cancerous state. When researchers removed or blocked KDM2B, the group 3 and 4 tumors grew much less effectively in lab and animal models. Thus, KDM2B may be a promising therapeutic target; however, more research is needed to determine whether this mechanism can be safely and successfully targeted in patients.